Bavituximab

• CAT Number: I042428
• CAS Number: 648904-28-3
• Molecular Weight: 145.3 (kDa)
• Purity: ≥95%

Bavituximab (Cat No.: I042428) is a chimeric monoclonal antibody that targets phosphatidylserine (PS), an immunosuppressive lipid abnormally exposed on the outer membrane of tumor and virus-infected cells. By binding PS, Bavituximab promotes immune activation, enhances macrophage-mediated phagocytosis, and supports anti-tumor immunity. It has been evaluated in clinical trials for cancers such as non-small cell lung cancer and hepatocellular carcinoma. Bavituximab represents a novel immunotherapeutic approach aimed at disrupting tumor immune evasion and enhancing the efficacy of conventional cancer treatments.

Reference

[1]. Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6.
[Content Brief]

[2]. Cheng X, et al. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591.
[Content Brief]